
ASND
Ascendis Pharma A/S
$230.83
-$0.32(-0.14%)
59
Overall
20
Value
90
Tech
68
Quality
Market Cap
$14.33B
Volume
908.47K
52W Range
$160.86 - $250.74
Target Price
$291.88
Company Overview
| Mkt Cap | $14.33B | Price | $230.83 |
| Volume | 908.47K | Change | -0.14% |
| P/E Ratio | -37.9 | Open | $233.60 |
| Revenue | $363.6M | Prev Close | $231.15 |
| Net Income | $-378.1M | 52W Range | $160.86 - $250.74 |
| Div Yield | N/A | Target | $291.88 |
| Overall | 59 | Value | 20 |
| Quality | 68 | Technical | 90 |
No chart data available
About Ascendis Pharma A/S
Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing TransCon-based therapies for unmet medical needs in Denmark, rest of Europe, North America, and internationally. The company offers SKYTROFA for treating pediatric patients with growth hormone deficiency; and YORVIPATH, a once-daily subcutaneous injection for the treatment of adults with chronic hypoparathyroidism. It also develops a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates. Ascendis Pharma A/S was incorporated in 2006 and is headquartered in Hellerup, Denmark.
Sector: Healthcare
Industry: Biotechnology
Latest News
Analysts Offer Insights on Healthcare Companies: Ascendis Pharma (ASND) and Corbus Pharmaceuticals (CRBP)
Christine Brown•2 days ago
Analysts’ Top Healthcare Picks: Amylyx Pharmaceuticals Inc (AMLX), Ascendis Pharma (ASND)
Catie Powers•4 days ago
Oppenheimer Sticks to Their Buy Rating for Ascendis Pharma (ASND)
TipRanks Auto-Generated Intelligence Newsdesk•5 days ago
Ascendis Pharma Grants New Employee Warrants as Part of Updated Equity Incentive Plan
TipRanks Auto-Generated Newsdesk•9 days ago
Ascendis Pharma (ASND) Gets a Buy from Leerink Partners
TipRanks Auto-Generated Intelligence Newsdesk•15 days ago
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | ASND | $230.83 | -0.1% | 908.47K |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |